Organ damage caused by medication is the most common reason for withdrawing drugs that have already been approved for the market. There is no reliable test system available at present to detect organ failure at an early stage. Organ failure is associated with a high mortality and can be caused by acute diseases or medication.
This gave rise to the development of a microtiter plate assay based on human cell-based biosensors that can be used to detect organ failure at an early stage in a clinical setting and to evaluate the toxicity of drugs and medical devices. By optimizing and standardizing the procedure, reliable statements can be made with regard to exogenous and endogenous toxicity.
The research group from the Northeast of Germany has sucessfully developed in vitro-tests for an early detection of organ failure and assessment of prognosis in critically ill patients regarding liver, nervous system and immune system. The in-vitro test systems are implemented to replace, reduce and refine (3R principle) animal trials. The assays are useable for pharmaceutical (toxicology, drug development, efficacy testing, bioactivity assays, quality control) and chemical industry (toxicity testing) as well as basic research. The following in-vitro test systems are established for investigation of hepatotoxicity, neurotoxicity and leukocyte immunoparalysis. All tests are performed according to DIN EN ISO/IEC 17025:2005-08 to ensure a high accuracy of results.
The research group is highly interested in common research and innovation projects. Companies and also research institutions that want to cooperate within Horizon 2020 or other research projects are welcome in order to further develop and apply the test systems and to look for a wider spectrum of application fields.
Partners could test (in-vitro) their products with regard to hepatotoxicity, neurotoxicity and leukocyt immunoparalysis.
Besides that, a technical cooperation with focus on using the existing equipment is also possible.
Outside of joint project acitivities the testing technologies can be made availabe by licensing agreements.